Clevudine (CAS 163252-36-6) Suppliers and Product Information

Clevudine is a fluorinated β-L nucleoside ***og used for the oral treatment of chronic HBV infection. It inhibits HBV DNA synthesis with an EC50 of 0.1 μM in HBV-expressing human hepatoma cell line 2.2.15, without showing cytotoxicity up to 200 μM. Clevudine is phosphorylated by cellular kinases to the active triphosphate derivative, which subsequently inhibits HBV DNA polymerase and HBV replication.

Frequently Asked Questions about Clevudine

Q: What is the main use of Clevudine?

A: Clevudine is primarily used as an antiviral drug for the treatment of chronic Hepatitis B virus (HBV) infection.

Q: How does Clevudine work?

A: Clevudine is phosphorylated by cellular kinases to its active triphosphate form, which then inhibits HBV DNA polymerase and viral replication. Interestingly, it acts as a non-competitive inhibitor of viral polymerase and inhibits HBV replication without being incorporated into the DNA.

Q: What are the common side effects of Clevudine?

A: The most commonly reported adverse events associated with Clevudine treatment include infection, asthenia, dyspepsia, abdominal pain, headache, and diarrhea.

Q: What is the pharmacokinetic profile of Clevudine?

A: Clevudine has a linear pharmacokinetic profile with a plasma half-life of approximately 60 hours. It becomes undetectable in plasma after 4 weeks following the cessation of dosing.